Latozinemab AL001
| 产品介绍 | Latozinemab (AL001) 是一种重组人源化抗 Sortilin 单克隆抗体。Latozinemab 以高亲和力有效结合 Sortilin，并阻断颗粒蛋白前体 (PGRN) 和 Sortilin 受体之间的相互作用。Latozinemab 具有引起额颞叶痴呆 (FTD) (FTD-GRN) 研究的颗粒蛋白原基因 (GRN) 突变的潜力。 |
|---|---|
| 生物活性 | Latozinemab (AL001) is a recombinant humanized anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research. |
| 体外研究 | |
| 体内研究 | |
| 体内研究 | |
| 性状 | |
| 溶解性数据 | |
| 运输条件 | |
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| 参考文献 |
浙公网安备 33010802013016号